Article Versions Notes

Hernández C, Porta M, Bandello F, Grauslund J, Harding SP, Aldington SJ, Egan C, Frydkjaer-Olsen U, García-Arumí J, Gibson J, et al. The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial. Journal of Clinical Medicine. 2020; 9(4):1233. https://doi.org/10.3390/jcm9041233

Hernández, Cristina, Massimo Porta, Francesco Bandello, Jakob Grauslund, Simon P. Harding, Stephen J. Aldington, Catherine Egan, Ulrik Frydkjaer-Olsen, José García-Arumí, Jonathan Gibson, and et al. 2020. "The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial" Journal of Clinical Medicine 9, no. 4: 1233. https://doi.org/10.3390/jcm9041233

Hernández, C., Porta, M., Bandello, F., Grauslund, J., Harding, S. P., Aldington, S. J., Egan, C., Frydkjaer-Olsen, U., García-Arumí, J., Gibson, J., Lang, G. E., Lattanzio, R., Massin, P., Midena, E., Ponsati, B., Ribeiro, L., Scanlon, P., Cunha-Vaz, J., & Simó, R., for the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). (2020). The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial. Journal of Clinical Medicine, 9(4), 1233. https://doi.org/10.3390/jcm9041233